Practice

4 Studies Highlight Biosimilar Switching's Effect on Patients With IBD

February 19th 2018

By Kelly Davio

At the European Crohn’s and Colitis Organisation’s 13th annual congress, held in Vienna, Austria, a number of studies explored switching from reference infliximab to its biosimilar.

PANTS Study Supports Effectiveness, Safety, and Immunogenicity of Biosimilar Infliximab

February 17th 2018

By Kelly Davio

Today, at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO), researchers released 12-month data from the Personalized Anti–Tumor Necrosis Factor (anti-TNF) Therapy in Crohn Disease (CD) Study (PANTS).

ASCO Issues Statement on Biosimilars in Oncology

February 16th 2018

By Kelly Davio

This week, the American Society of Clinical Oncology (ASCO) released a new statement that seeks to offer clinicians guidance on the use of biosimilars in oncology as a wave of patent expirations is expected to bring more anti-cancer and supportive care biosimilars to the US market.

TITRATE Study to Investigate Intensive Management of RA

February 16th 2018

By Samantha DiGrande

The TITRATE study is designed to investigate whether intensive management of RA leads to a greater number of remissions at 12 months, in addition to examining levels of disability, quality of life and acceptability, and cost-effectiveness.

Rheumatologist Sees Gray Areas in ACR White Paper on Biosimilars

February 14th 2018

By Kelly Davio

According to Roy Fleischmann, MD, a recent American College of Rheumatology (ACR) white paper appropriately describes issues including the nomenclature of biosimilars, the biosimilar approval pathway, and differences between biosimilars for biologic drugs and generics for small-molecule drugs. However, he takes issue with ACR's stance on substitution, extrapolation, and interchangeability.

Roche Releases Phase 2 Data for Novel Drug as Anti-VEGF Biosimilars Advance

February 14th 2018

By The Center for Biosimilars Staff

Roche has released positive phase 2 data for its proposed novel anti–vascular endothelial growth factor and anti–angiopoietin-2 bispecific antibody, RG7716.

Biosimilar Adalimumab, Exemptia, Has Limited Efficacy in Treating Ulcerative Colitis

February 13th 2018

By Kelly Davio

Researchers found that the biosimilar offered only limited efficacy when used for induction of remission in patients with moderate to severe ulcerative colitis that was refractory to treatment with steroids.

Study: Rituximab Effective and Well Tolerated in Treating Nephrotic Syndrome

February 12th 2018

By The Center for Biosimilars Staff

Some case reports have suggested that rituximab can effectively treat nephrotic syndrome, and a recent study sought to assess the safety and effectiveness of rituximab in treating patients who have steroid- and cyclosporine-resistant pediatric nephrotic syndrome.

Novartis Gains Label Expansion for Secukinumab

February 10th 2018

By The Center for Biosimilars Staff

Novartis announced on Thursday that the FDA has approved a label update for secukinumab (Cosentyx) to include moderate to severe scalp psoriasis, a particularly challenging form of psoriasis to treat, and a condition that affects approximately half of patients with psoriasis.

The Top 5 Biosimilars Articles for the Week of February 5

February 9th 2018

The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 5, 2018.